Skip to Content
You are currently on the new version of our website. Access the old version .

35 Results Found

  • Case Report
  • Open Access
2 Citations
66,236 Views
7 Pages

Serious and Progressive Neuropathy Presumably Post-Shingrix Vaccination

  • Michael J. Wons,
  • Avani Vaghela,
  • Amna Khalid and
  • Benjamin D. Brooks

13 January 2024

We present a case of serious and progressive neuropathy shortly following the administration of the herpes zoster subunit (HZ/su) vaccine, otherwise known as Shingrix. The progressive neuropathy occurred a week following the vaccination and progresse...

  • Case Report
  • Open Access
1 Citations
30,492 Views
8 Pages

Prolonged Neurological and Musculoskeletal Symptoms Following Shingrix Vaccination

  • Sabrina Hollar,
  • Amna Khalid,
  • Benjamin D. Brooks and
  • Michael Wons

9 October 2024

Background and Clinical Significance: The recombinant zoster vaccine (Shingrix) helps prevent shingles and its complications in adults 50 and older. While minor side effects are common, severe adverse reactions are thought to be rare, and long-term s...

(This article belongs to the Section Epidemiology/Public Health)
  • Article
  • Open Access
4 Citations
2,814 Views
14 Pages

Anti-Herpes Zoster Vaccination of Fragile Patients in Hospital Setting: A Nudge Intervention in Italy

  • Francesco De Caro,
  • Francesca Malatesta,
  • Nadia Pecoraro,
  • Mario Capunzo and ,
  • Luna Carpinelli,
  • Simona Caruccio,
  • Giuseppina Cersosimo,
  • Maria Costantino,
  • Claudio Giordano and
  • Giuseppina Moccia
  • + 11 authors+ 6 authors

19 April 2024

Background: A nudge intervention against Herpes Zoster, created and implemented in Italy, is presented in order to administer the Shingrix vaccine on a sample of frail patients, as required by the National Prevention Plan. Individual and contextual f...

(This article belongs to the Special Issue Vaccination Uptake and Public Health)
  • Review
  • Open Access
300 Views
10 Pages

Cutaneous Events After Recombinant Zoster Vaccination and Shoulder Injury Related to Zoster Vaccine Administration: A Narrative Review

  • Carlo Ciccullo,
  • Arturo Ciccullo,
  • Sonia Farah,
  • Claudia Bevilacqua and ,
  • Marco Grassi,
  • Luca Farinelli,
  • Edoardo De Simoni,
  • Elisa Molinelli,
  • Oriana Simonetti and
  • Antonio P. Gigante
  • + 6 authors+ 1 author

15 October 2026

Background: Herpes zoster results from the reactivation of varicella–zoster virus (VZV), with incidence increasing with age and immunosuppression. The recombinant zoster vaccine (RZV, Shingrix®, GlaxoSmithKline Biologicals SA, Rixensart, Be...

(This article belongs to the Section Epidemiology & Public Health)
  • Brief Report
  • Open Access
9 Citations
3,360 Views
12 Pages

13 January 2025

Background/Objectives: Approved mRNA vaccines commonly use sequences modified with pseudouridine to enhance translation efficiency and mRNA stability. However, this modification can result in ribosomal frameshifts, reduced immunogenicity, and higher...

(This article belongs to the Special Issue Evaluating the Immune Response to RNA Vaccine)
  • Article
  • Open Access
2 Citations
1,788 Views
11 Pages

Enhancing Herpes Zoster Vaccination Rates Among Oncology Outpatients: Impact of an In-House Vaccination Initiative

  • Alberto Giuseppe Agostara,
  • Silvia Della Torre,
  • Sara Di Bella,
  • Michela Pelliccione and ,
  • Paola Candido,
  • Valeria Smiroldo,
  • Davide Toniolo,
  • Francesca Zannier and
  • Roberto Bollina
  • + 4 authors+ 0 author

30 October 2025

Background: Herpes zoster (HZ) poses significant risks to immunocompromised individuals, particularly cancer patients receiving systemic therapies. The recombinant zoster vaccine (RZV, Shingrix®) provides strong and durable protection against HZ...

(This article belongs to the Section Cancer Immunology and Immunotherapy)
  • Article
  • Open Access
1 Citations
1,863 Views
12 Pages

Real-World Safety and Herpes Zoster Outcomes After Recombinant Zoster Vaccination in Inflammatory Bowel Disease

  • Gian Mario Morrone,
  • Sara Sandri,
  • Marta Vernero,
  • Angelo Armandi and ,
  • Gian Paolo Caviglia and
  • Davide Giuseppe Ribaldone
  • + 1 author+ 0 author

7 July 2026

Background/Objectives: Patients with inflammatory bowel disease (IBD) are at an increased risk of herpes zoster (HZ), particularly during immunosuppressive treatment. To assess the safety of the recombinant zoster vaccine (RZV, Shingrix®) and des...

(This article belongs to the Topic Advances in Gastrointestinal and Liver Disease: From Physiological Mechanisms to Clinical Practice, 2nd Edition)
  • Article
  • Open Access
4 Citations
3,837 Views
11 Pages

Antibody Responses Following Primary Immunization with the Recombinant Herpes Zoster Vaccine (Shingrix®) in VZV Seronegative Immunocompromised Adults

  • Andrea Wessely,
  • Ines Zwazl,
  • Melita Poturica,
  • Lukas Weseslindtner and ,
  • Michael Kundi,
  • Ursula Wiedermann and
  • Angelika Wagner
  • + 2 authors+ 0 author

Background: Immunocompromised patients are at risk of severe varicella zoster virus (VZV) infection and reactivation. In VZV seronegative immunocompromised persons, live-attenuated VZV vaccination is contraindicated, thus the recombinant herpes zoste...

(This article belongs to the Special Issue Varicella and Zoster Vaccination)
  • Article
  • Open Access
8 Citations
3,582 Views
8 Pages

Adherence to Herpes Zoster (Shingles) Catch-Up Campaign at the Romagna Local Health Authority (Italy), a Multi-Center Retrospective Observational Study

  • Andrea Ceccarelli,
  • Susan Scrimaglia,
  • Virginia Fossi,
  • Luigi Ceccaroni and ,
  • Andrea Federici,
  • Chiara Reali,
  • Raffaella Angelini,
  • Giulia Silvestrini,
  • Francesco Sintoni and
  • Marco Montalti
  • + 8 authors+ 3 authors

21 October 2022

Herpes Zoster (shingles) is an infection that occurs when varicella-zoster virus reactivates from the latent state. Incidence and severity of Herpes Zoster disease increase with age. Antiviral drugs are the elective treatment; however, prevention of...

(This article belongs to the Special Issue Feature Papers of Epidemiology and Vaccines 2.0)
  • Article
  • Open Access
5 Citations
2,019 Views
12 Pages

Effectiveness and Safety of Recombinant Zoster Vaccine in Rheumatic Diseases: Real-World Evidence from a Single-Centre Italian Cohort

  • Silvia Valentini,
  • Jurgen Sota,
  • Irene Fineschi,
  • Edoardo Conticini and ,
  • Estrella Garcia-Gonzalez,
  • Emilio D’Ignazio,
  • Marco Bardelli,
  • Stefano Gentileschi,
  • Marta Fabbroni and
  • Caterina Baldi
  • + 10 authors+ 5 authors

5 December 2025

Background: Patients with rheumatic diseases (RMDs) are at increased risk of herpes zoster (HZ), particularly when receiving immunosuppressive treatment. While recombinant zoster vaccine (RZV) has shown high effectiveness in the general population, e...

(This article belongs to the Special Issue Immunogenicity, Safety, and Coverage of Vaccines in Patients with Autoimmune Diseases)
  • Article
  • Open Access
6 Citations
2,786 Views
6 Pages

Herpes Zoster Vaccination Rates in Hematological and Oncological Patients—Stock Taking 2 Years after Market Approval

  • Til Ramón Kiderlen,
  • Katrin Trostdorf,
  • Nicola Delmastro,
  • Arne Salomon and ,
  • Maike de Wit and
  • Mark Reinwald
  • + 1 author+ 0 author

12 August 2022

Background: Vaccinations have the potential to significantly lower the burden of disease for many major infections in the high-risk population of hematological and oncological patients. In this regard Shingrix®, an inactivated Varicella Zoster Vi...

(This article belongs to the Section Public Health and Preventive Medicine)
  • Article
  • Open Access
34 Citations
12,429 Views
19 Pages

Recombinant Glycoprotein E of Varicella Zoster Virus Contains Glycan-Peptide Motifs That Modulate B Cell Epitopes into Discrete Immunological Signatures

  • Rickard Nordén,
  • Jonas Nilsson,
  • Ebba Samuelsson,
  • Christian Risinger and ,
  • Carina Sihlbom,
  • Ola Blixt,
  • Göran Larson,
  • Sigvard Olofsson and
  • Tomas Bergström
  • + 4 authors+ 0 author

22 February 2019

A recombinant subunit vaccine (Shingrix®) was recently licensed for use against herpes zoster. This vaccine is based on glycoprotein E (gE) of varicella zoster virus (VZV), the most abundantly expressed protein of VZV, harboring sites for N- and...

(This article belongs to the Special Issue Protein–Carbohydrate Interactions: Structure–Function Relationships)
  • Article
  • Open Access
4 Citations
2,931 Views
15 Pages

Immunogenicity in Mice Immunized with Recombinant Adenoviruses Expressing Varicella-Zoster Virus Envelope Glycoprotein E

  • Yanpeng Zheng,
  • Lei Huang,
  • Huiru Ding,
  • Huawei Xu and ,
  • Rigan Shu,
  • Jiemei Yu,
  • Xianglei Peng,
  • Yuanhui Fu and
  • Jinsheng He
  • + 4 authors+ 0 author

22 November 2023

Herpes zoster (HZ) is a disease caused by the reactivation of latent varicella-zoster virus (VZV). The subunit vaccine, Shingrix®, and live attenuated vaccine, Zostavax®, could be used as an HZ vaccine that prevents HZ from being developed du...

(This article belongs to the Section Viral Immunology, Vaccines, and Antivirals)
  • Article
  • Open Access
23 Citations
4,994 Views
17 Pages

Hematopoietic stem cell transplant (HSCT) recipients have a high risk of developing primary varicella-zoster virus (VZV) infection and reactivation. VZV vaccination may prevent infection and reactivation. In the current study, recipients of allogenei...

(This article belongs to the Special Issue Herpesvirus-Specific Immunomonitoring in Patient Groups of Increased Risk)
  • Article
  • Open Access
14 Citations
4,516 Views
14 Pages

Prospective, Longitudinal Study on Specific Cellular Immune Responses after Vaccination with an Adjuvanted, Recombinant Zoster Vaccine in Kidney Transplant Recipients

  • Monika Lindemann,
  • Charleen Baumann,
  • Benjamin Wilde,
  • Anja Gäckler and ,
  • Lara Meller,
  • Peter A. Horn,
  • Adalbert Krawczyk and
  • Oliver Witzke
  • + 3 authors+ 0 author

Solid organ transplant recipients have an up to ninefold higher risk of varicella–zoster virus (VZV) reactivation than the general population. Due to lifelong immunosuppressive therapy, vaccination against VZV may be less effective in kidney tr...

(This article belongs to the Special Issue Vaccine Immunology)
  • Article
  • Open Access
24 Citations
5,455 Views
17 Pages

Varicella zoster virus (VZV) causes two diseases: varicella upon primary infection and herpes zoster when latent viruses in the sensory ganglia reactivate. While varicella vaccines depend on humoral immunity to prevent VZV infection, cell-mediated im...

(This article belongs to the Special Issue Drug Repurposing and Delivery Systems for Immunotherapy)
  • Article
  • Open Access
10 Citations
3,930 Views
9 Pages

18 August 2022

Increasing numbers of patients with zoster were reported recently, and recombinant zoster vaccine (Shingrix®) was licensed using the AS01B adjuvant system. Although it induces highly effective protection, a high incidence of local adverse events...

(This article belongs to the Topic Animal Model in Biomedical Research)
  • Article
  • Open Access
10 Citations
3,586 Views
12 Pages

Comparison of the Immunogenicity of the LZ901 Vaccine and HZ/su Vaccine in a Mouse Model

  • Yaru Quan,
  • Chunxia Liu,
  • Xu Lu,
  • Xi Kong and ,
  • Shuai Yang,
  • Jian Kong,
  • Wenyan Wan,
  • Kaiqin Wang,
  • Kangwei Xu and
  • Ling Peng
  • + 5 authors+ 0 author

15 July 2024

Herpes zoster (HZ) is an infectious disease caused by the reactivation of varicella zoster virus (VZV), with 68% of cases occurring in adults over 50 years of age. HZ/su (Shingrix®) was approved by the Food and Drug Administration in 2017 for the...

  • Article
  • Open Access
9 Citations
3,918 Views
15 Pages

Glycoprotein E-Displaying Nanoparticles Induce Robust Neutralizing Antibodies and T-Cell Response against Varicella Zoster Virus

  • Hong Wang,
  • Sibo Zhang,
  • Wenhui Xue,
  • Yarong Zeng and ,
  • Liqin Liu,
  • Lingyan Cui,
  • Hongjing Liu,
  • Yuyun Zhang,
  • Lin Chen and
  • Shaowei Li
  • + 14 authors+ 9 authors

12 September 2024

The Varicella zoster virus (VZV), responsible for both varicella (chickenpox) and herpes zoster (shingles), presents significant global health challenges. While primary VZV infection primarily affects children, leading to chickenpox, reactivation in...

(This article belongs to the Collection Feature Papers in Molecular Pathology, Diagnostics, and Therapeutics)
  • Review
  • Open Access
1,008 Views
22 Pages

3 October 2026

Background/Objectives: The recombinant zoster vaccine (RZV), Shingrix®, has shown great efficacy in protecting against herpes zoster. However, emerging evidence suggests that this RZV might provide benefits that extend beyond preventing varicella...

(This article belongs to the Special Issue From Knowledge to Action: Advances in Herpes Zoster Vaccine and Vaccination)
  • Review
  • Open Access
125 Citations
15,791 Views
18 Pages

Saponin adjuvants have been extensively studied for their use in veterinary and human vaccines. Among them, QS-21 stands out owing to its unique profile of immunostimulating activity, inducing a balanced Th1/Th2 immunity, which is valuable to a broad...

(This article belongs to the Special Issue Vaccine Formulation for Infectious Diseases and Adjuvant Mechanisms of Action)
  • Article
  • Open Access
11 Citations
4,877 Views
20 Pages

Adjuvant Effects of a New Saponin Analog VSA-1 on Enhancing Homologous and Heterosubtypic Protection by Influenza Virus Vaccination

  • Noopur Bhatnagar,
  • Ki-Hye Kim,
  • Jeeva Subbiah,
  • Bo Ryoung Park and ,
  • Pengfei Wang,
  • Harvinder Singh Gill,
  • Bao-Zhong Wang and
  • Sang-Moo Kang
  • + 3 authors+ 0 author

24 August 2022

Adjuvants can increase the magnitude and durability of the immune response generated by the vaccine antigen. Aluminum salts (Alum) remain the main adjuvant licensed for human use. A few new adjuvants have been licensed for use in human vaccines since...

(This article belongs to the Special Issue Vaccine Adjuvants Research)
  • Review
  • Open Access
14 Citations
8,714 Views
21 Pages

Research Progress on Varicella-Zoster Virus Vaccines

  • Hongjing Liu,
  • Lingyan Cui,
  • Sibo Zhang,
  • Hong Wang and ,
  • Wenhui Xue,
  • Hai Li,
  • Yuyun Zhang,
  • Lin Chen,
  • Ying Gu and
  • Shaowei Li
  • + 7 authors+ 2 authors

Varicella-zoster virus (VZV) poses significant public health challenges as the etiological agent of varicella (chickenpox) and herpes zoster (HZ), given its high transmissibility and potential for severe complications. The introduction of VZV vaccine...

(This article belongs to the Special Issue Varicella and Zoster Vaccination)
  • Article
  • Open Access
25 Citations
6,983 Views
13 Pages

25 March 2021

Theoretically, the subunit herpes zoster vaccine ShingrixTM could be used as a varicella vaccine that avoids the risk of developing shingles from vaccination, but bedside mixing strategies and the limited supply of the adjuvant component QS21 have ma...

(This article belongs to the Special Issue Vaccine Formulation for Infectious Diseases and Adjuvant Mechanisms of Action)
  • Article
  • Open Access
12 Citations
5,724 Views
16 Pages

Baculovirus Display of Varicella–Zoster Virus Glycoprotein E Induces Robust Humoral and Cellular Immune Responses in Mice

  • Wenhui Xue,
  • Tingting Li,
  • Sibo Zhang,
  • Yingbin Wang and ,
  • Minqing Hong,
  • Lingyan Cui,
  • Hong Wang,
  • Yuyun Zhang,
  • Tingting Chen and
  • Shaowei Li
  • + 14 authors+ 9 authors

16 August 2022

Varicella–zoster virus (VZV) is the causative agent of varicella and herpes zoster (HZ) and can pose a significant challenge to human health globally. The initial VZV infection—more common in children—causes a self-limiting chicken...

(This article belongs to the Special Issue Advances in Antiviral Immunity and Virus Vaccines)
  • Communication
  • Open Access
3 Citations
2,634 Views
9 Pages

Surveying a Sample of the Spanish Ophthalmologic Community about Vaccination against Herpes Zoster

  • Alberto Sánchez-Mellado,
  • Luis Alcaraz-Clemente,
  • Marina Rodríguez-Calvo-de-Mora,
  • José-María Sánchez-González and ,
  • Santiago Ortiz-Perez and
  • Carlos Rocha-de-Lossada
  • + 1 author+ 0 author

There are currently two authorized vaccines against herpes zoster (HZ) that have been shown to be safe and effective in its prevention: Zostavax, a zoster vaccine live (ZVL), and Shingrix, a recombinant zoster Vaccine (RZV). Because ophthalmologists...

(This article belongs to the Section Vaccines and Public Health)
  • Article
  • Open Access
1 Citations
1,222 Views
17 Pages

Immunogenicity of a Recombinant Zoster Vaccine (gE/BFA01) in Mice

  • Yaru Quan,
  • Shiqiang Luo,
  • Shuang Wu,
  • Kaiqin Wang and ,
  • Lixing Hu,
  • Yihuan Hao,
  • Kangwei Xu and
  • Yong Liu
  • + 3 authors+ 0 author

30 December 2025

Varicella-zoster virus (VZV) is a human neurotropic herpesvirus. The primary infection with VZV causes chickenpox and establishes latency in sensory and dorsal root ganglia. Viral reactivation leads to herpes zoster (HZ), which is accompanied by comp...

(This article belongs to the Section Viral Immunology, Vaccines, and Antivirals)
  • Article
  • Open Access
18 Citations
7,468 Views
12 Pages

Cost-Effectiveness Analysis of Herpes Zoster Vaccination in a Chinese Population: Recombinant Subunit Vaccine versus Live Attenuated Vaccine

  • Jiaqi Wang,
  • Pengfei Jin,
  • Hui Jin,
  • Qiang Wang and ,
  • Fengcai Zhu and
  • Jingxin Li
  • + 1 author+ 0 author

1 August 2024

Background: Currently, the recombinant subunit vaccine and live attenuated vaccine in the prevention of herpes zoster are approved for marketing in China. This study aims to evaluate the cost-effectiveness of the recombinant subunit vaccine and the l...

(This article belongs to the Special Issue Estimating Vaccines' Value and Impact)
  • Review
  • Open Access
32 Citations
15,211 Views
17 Pages

The development of effective vaccines continues to be a key goal for public health bodies, governments, funding bodies and pharmaceutical companies. With new vaccines such as Shingrix targeting Shingles and Bexsero for Meningitis B, licensed in recen...

(This article belongs to the Special Issue T Cell Memory to Vaccination)
  • Article
  • Open Access
1,156 Views
15 Pages

Background: The recombinant zoster vaccine (RZV) has been shown to reduce the risk of dementia and delay cognitive decline. However, economic evaluations in populations with mild cognitive impairment (MCI), particularly those incorporating cognitive...

(This article belongs to the Special Issue Vaccination and Public Health in the 21st Century, 2nd Edition)
  • Article
  • Open Access
21 Citations
7,347 Views
18 Pages

Structures of the Varicella Zoster Virus Glycoprotein E and Epitope Mapping of Vaccine-Elicited Antibodies

  • Wayne D. Harshbarger,
  • Genevieve Holzapfel,
  • Nishat Seraj,
  • Sai Tian and ,
  • Chelsy Chesterman,
  • Zongming Fu,
  • Yan Pan,
  • Claire Harelson,
  • Dongjun Peng and
  • James Williams
  • + 9 authors+ 4 authors

27 September 2024

Background: Varicella zoster virus (VZV) is the causative agent for chickenpox and herpes zoster (HZ, shingles). HZ is a debilitating disease affecting elderly and immunocompromised populations. Glycoprotein E (gE) is indispensable for viral replicat...

  • Article
  • Open Access
17 Citations
5,972 Views
12 Pages

Comparison of the Immune Effects of an mRNA Vaccine and a Subunit Vaccine against Herpes Zoster Administered by Different Injection Methods

  • Kangyang Lin,
  • Han Cao,
  • Ning Luan,
  • Yunfei Wang and ,
  • Jingping Hu and
  • Cunbao Liu
  • + 1 author+ 0 author

20 May 2023

Previous studies have shown that the herpes zoster subunit vaccine Shingrix™ performs well in clinical trials. However, the key ingredient in its adjuvant, QS21, is extracted from rare plants in South America, so vaccine production is limited....

(This article belongs to the Section Vaccines Against Tropical and Other Infectious Diseases)
  • Systematic Review
  • Open Access
988 Views
14 Pages

10 August 2026

Background/Objectives: Dementia represents a major global health challenge, and preventive strategies remain limited. Observational studies have suggested a possible association between herpes zoster vaccination (HZV) and dementia risk, although the...

(This article belongs to the Section Epidemiology and Vaccination)
  • Study Protocol
  • Open Access
2 Citations
3,311 Views
15 Pages

Immune Response to an Adjuvanted Recombinant Zoster Vaccine in Japanese Patients with Rheumatoid Arthritis Receiving Upadacitinib (End Zoster-J Study): Study Protocol for an Exploratory Parallel Triple-Arm Prospective Trial

  • Ryu Watanabe,
  • Hisako Fujii,
  • Takumi Imai,
  • Yuki Furusawa and ,
  • Masao Katsushima,
  • Kazuo Fukumoto,
  • Yutaro Yamada,
  • Kenji Mamoto,
  • Tadashi Okano and
  • Motomu Hashimoto
  • + 6 authors+ 1 author

2 December 2024

Background: Janus kinase (JAK) inhibitors have emerged as a new class of disease-modifying anti-rheumatic drugs in the treatment of rheumatoid arthritis (RA). However, herpes zoster is one of the common adverse events of JAK inhibitors, including upa...

(This article belongs to the Section Immunology & Rheumatology)
  • Review
  • Open Access
2 Citations
1,731 Views
14 Pages

11 December 2025

Background: Cutaneous viral infections, defined as viral pathogens that either primarily affect the skin (e.g., herpesviruses, enteroviruses) or frequently produce dermatologic manifestations despite systemic tropism (e.g., HIV, SARS-CoV-2), can trig...

(This article belongs to the Section Clinical Neurology)